Boston Scientific Names Fitzgerald COO, Creates Three Segments
Image
Marlborough, Mass. – October 07, 2026 -- Boston Scientific Corporation (NYSE: BSX) has appointed Joseph M. Fitzgerald as executive vice president and chief operating officer, effective Jan. 1, 2027, a move paired with a restructuring of the company into three reportable business segments.
Boston Scientific splits operations into Interventional Therapies, Rhythm Solutions and MedSurg
The new segment structure takes effect Jan. 1, 2027. Interventional Therapies will combine the Interventional Cardiology, Vascular Therapies, and Interventional Oncology & Embolization businesses, and will absorb the Penumbra business once that acquisition closes. Rhythm Solutions will house Electrophysiology, WATCHMAN, and Cardiac Rhythm Management & Diagnostics. MedSurg will encompass Endoscopy, Urology and Neuromodulation.